David G Covell

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. ncbi request reprint Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases
    David G Covell
    National Cancer Institute Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, Maryland, USA
    Proteins 59:403-33. 2005
  2. ncbi request reprint Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data
    David G Covell
    National Cancer Institute Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, MD 21702, USA
    Mol Cancer Ther 6:2261-70. 2007
  3. ncbi request reprint Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data
    Anders Wallqvist
    Science Applications International Corporation, National Cancer Institute at Frederick, National Institutes of Health Frederick, MD 21702, USA
    Bioinformatics 19:2212-24. 2003
  4. ncbi request reprint Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12
    Ruoli Bai
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 279:30731-40. 2004
  5. pmc Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen
    David G Covell
    Developmental Therapeutics Program, Frederick National Laboratory, National Institutes of Health, Frederick, Maryland, United States of America
    PLoS ONE 7:e44631. 2012
  6. ncbi request reprint Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen
    Ruili Huang
    Laboratory of Computational Technologies, Developmental Therapeutics Program, Screening Technologies Branch, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Genomics 87:315-28. 2006
  7. pmc Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines
    Constance J Glover
    Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Biochem Pharmacol 73:331-40. 2007
  8. ncbi request reprint Evaluating chemical structure similarity as an indicator of cellular growth inhibition
    Anders Wallqvist
    National Cancer Institute, Developmental Therapeutics Program, Screening Technologies Branch, Frederick, Maryland 21702, USA
    J Chem Inf Model 46:430-7. 2006
  9. ncbi request reprint Molecular classification of cancer: unsupervised self-organizing map analysis of gene expression microarray data
    David G Covell
    National Cancer Institute Frederick, Science Applications International Corporation Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, Maryland 21702, USA
    Mol Cancer Ther 2:317-32. 2003
  10. ncbi request reprint Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology
    Anders Wallqvist
    Science Applications International Corporation, Frederick, Maryland 21702, USA
    Mol Cancer Ther 1:311-20. 2002

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases
    David G Covell
    National Cancer Institute Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, Maryland, USA
    Proteins 59:403-33. 2005
    ..e., few) molecular targets. Applications of data mining strategies that jointly utilize tumor cell screening, genomic, and structural data are presented for hypotheses generation and identifying novel anticancer candidates...
  2. ncbi request reprint Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data
    David G Covell
    National Cancer Institute Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, MD 21702, USA
    Mol Cancer Ther 6:2261-70. 2007
    ..These results are extended to applications of two-dimensional structural features to further refine compound selections based on tumor panel sensitivity obtained from tumor screening results...
  3. ncbi request reprint Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data
    Anders Wallqvist
    Science Applications International Corporation, National Cancer Institute at Frederick, National Institutes of Health Frederick, MD 21702, USA
    Bioinformatics 19:2212-24. 2003
    ....
  4. ncbi request reprint Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12
    Ruoli Bai
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 279:30731-40. 2004
    ..Dolastatin 15 and cryptophycin 1 could also be docked into positions that overlapped more extensively with the docked dolastatin 10 than with each other. This result was consistent with the observed binding properties of these peptides...
  5. pmc Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen
    David G Covell
    Developmental Therapeutics Program, Frederick National Laboratory, National Institutes of Health, Frederick, Maryland, United States of America
    PLoS ONE 7:e44631. 2012
    ..The data used in this analysis is available at http://pubchem.ncbi.nlm.nih.gov/andhttp://www.ncbi.nlm.nih.gov/projects/geo (GPL96, GSE32474)...
  6. ncbi request reprint Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen
    Ruili Huang
    Laboratory of Computational Technologies, Developmental Therapeutics Program, Screening Technologies Branch, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Genomics 87:315-28. 2006
    ..The knowledge of the nature of gene expression regulation and biological pathways can be applied to understanding the mechanism by which small drug molecules interfere with biological systems...
  7. pmc Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines
    Constance J Glover
    Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Biochem Pharmacol 73:331-40. 2007
    ..Our findings thus fortify the appeal of mitochondrial complex I as a possible anticancer molecular target and provide a data mining strategy for selecting candidate inhibitors for further testing...
  8. ncbi request reprint Evaluating chemical structure similarity as an indicator of cellular growth inhibition
    Anders Wallqvist
    National Cancer Institute, Developmental Therapeutics Program, Screening Technologies Branch, Frederick, Maryland 21702, USA
    J Chem Inf Model 46:430-7. 2006
    ..Structurally and functionally similar compounds can have distinguishable biological responses reflecting different mechanisms of action...
  9. ncbi request reprint Molecular classification of cancer: unsupervised self-organizing map analysis of gene expression microarray data
    David G Covell
    National Cancer Institute Frederick, Science Applications International Corporation Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, Maryland 21702, USA
    Mol Cancer Ther 2:317-32. 2003
    ..Discussions about the utility of this method and the quality of data needed for accurate tumor classifications are provided...
  10. ncbi request reprint Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology
    Anders Wallqvist
    Science Applications International Corporation, Frederick, Maryland 21702, USA
    Mol Cancer Ther 1:311-20. 2002
    ..The details of the 11 verifiable cases and the concordant gene subsets are provided. Discussions about the prospects of using this approach as a data mining tool are included...
  11. ncbi request reprint Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines
    Anders Wallqvist
    Science Applications International Corporation, NCI Frederick, P O Box B, Frederick, MD 21702, USA
    Mol Pharmacol 69:737-48. 2006
    ....
  12. ncbi request reprint Mining the NCI screening database: explorations of agents involved in cell cycle regulation
    Anders Wallqvist
    NCI Frederick, SAIC Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Bldg 1052, Room 238, Frederick, MD 21702, USA
    Prog Cell Cycle Res 5:173-9. 2003
    ..These results are consistent with the proposed inactivity of the CYP1A1-mediated metabolism of benzothiazole and the antitumor activity of the metabolically resistant halogenated forms...
  13. ncbi request reprint Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues
    Ruili Huang
    Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 5:2417-27. 2006
    ..These results can serve as guidelines for selecting novel agents that have the potential to specifically target a particular pathway that has relevance in cancer...
  14. pmc Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets
    David G Covell
    Developmental Therapeutics Program, National Cancer Institute, Frederick National Laboratory for Cancer Research FNLCR, Frederick, MD, USA
    PLoS ONE 7:e48023. 2012
    ....
  15. ncbi request reprint Anticancer metal compounds in NCI's tumor-screening database: putative mode of action
    Ruili Huang
    National Cancer Institute at Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, MD 21702, USA
    Biochem Pharmacol 69:1009-39. 2005
    ..Taken together, our results expand the knowledge base available for evaluating, designing and developing new metal-based anticancer drugs that may provide the basis for target-specific therapeutics...
  16. ncbi request reprint Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action
    Ruili Huang
    Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    J Med Chem 49:1964-79. 2006
    ..Finally, we offer a strategy to exploit this relationship for future mining of novel anticancer candidates...
  17. ncbi request reprint Application of high-throughput, molecular-targeted screening to anticancer drug discovery
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute Frederick, Maryland 21702 1201, USA
    Curr Top Med Chem 2:229-46. 2002
    ..In this article we discuss the application of high-throughput screening to anti-cancer drug discovery, with special reference to approaches used at the U.S. National Cancer Institute...
  18. ncbi request reprint Antimitotic peptides and depsipeptides
    Ernest Hamel
    National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    Curr Med Chem Anticancer Agents 2:19-53. 2002
    ..We also summarize initial efforts by computer modeling to decipher a pharmacophore among the diverse structures of these peptides and depsipeptides...
  19. ncbi request reprint Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors
    Anders Wallqvist
    Laboratory of Computational Technologies, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    J Chem Inf Model 47:1414-27. 2007
    ..Our analysis demonstrates that chemoinformatic studies utilizing a combination of xenograft data and in vitro preclinical testing offer an effective means to identify compound classes with superior efficacy and reduced toxicity...
  20. pmc A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept
    Susan D Mertins
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, MD, USA
    PLoS ONE 8:e57099. 2013
    ....
  21. ncbi request reprint Connecting chemosensitivity, gene expression and disease
    David G Covell
    Laboratory of Computational Technologies, Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA
    Trends Pharmacol Sci 29:1-5. 2008
    ..Elegantly simple in concept, the covariation of genetic and chemosensitivity readouts provide a hypothetical link for relating compounds through genomic expression profiles to underlying biology...
  22. ncbi request reprint Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction
    Gabriela Tudor
    Science Applications International Corp, National Cancer Institute, Frederick, MD, USA
    Anticancer Drugs 16:381-91. 2005
    ..Furthermore, the high cytotoxicity of RH1 in the leukemia/lymphoma subpanel of the NCI in vitro cell line screen would suggest an empirical rationale for the utilization of this compound in the treatment of these malignancies...
  23. ncbi request reprint (-)-Doliculide, a new macrocyclic depsipeptide enhancer of actin assembly
    Ruoli Bai
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 277:32165-71. 2002
    ..We found that the segment of (-)-doliculide that best overlapped the other molecules encompassed its phenyl and isopropyl side chains and the portion of the macrocycle between these substituents...
  24. ncbi request reprint Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity
    Andrew G Stephen
    Protein Chemistry Laboratory, SAIC Frederick, Inc, NCI Frederick, 21702, Frederick, MD, USA
    Biochem Biophys Res Commun 296:1228-37. 2002
    ..Molecular modeling predicts that these hydroxyl groups would bind to the amide nitrogen of Gly(35) with other contacts at the carbonyl oxygens of Gly(40) and Lys(33)...
  25. ncbi request reprint Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities
    Alfred A Rabow
    Science Applications International Corporation and Developmental Therapeutics Program, DCTD, National Cancer Institute NIH, Frederick, MD 21702, USA
    J Med Chem 45:818-40. 2002
    ..The advantages of a global analysis of the complete screening data set are discussed...
  26. pmc Relating molecular flexibility to function: a case study of tubulin
    Ozlem Keskin
    Computational Technologies Laboratory, Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute Frederick, National Institutes of Health, Frederick, Maryland 21702 USA
    Biophys J 83:663-80. 2002
    ..Our analysis provides insights into relationships between intramolecular tubulin movements of MT organization and function...
  27. ncbi request reprint Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
    Anders Wallqvist
    Science Applications International Corp, National Cancer Institute, NIH, Bethesda, MD, USA
    Mol Cancer Ther 4:1559-68. 2005
    ..We suggest that compounds identified in this study may represent new classes of potential anticancer agents...